Blood Tests Called For, Then Refused: A Three-Day Contradiction

The Sequence

Two documented events, three days apart:

1. 3 March 2026: The Leader of Wyre Council publicly called for PFAS blood testing for residents living in proximity to the Hillhouse industrial estate, and for a “proper inquiry” into local health. The council leader described Wyre as having been “hung out to dry” by central government (ENDS Report, 3 March 2026).

2. 6 March 2026: Wyre Council formally responded to an FOI request asking why biomonitoring had not been conducted. The council’s stated reasons for refusing biomonitoring were:

   • Blood testing would be “not appropriate”
   • Results would be “uninterpretable”
   • Testing would cause “additional distress” to residents

A gap of three days elapsed between a senior elected official publicly calling for blood tests and Wyre Council’s formal position — as stated in an FOI response — declining to conduct them.

Source for FOI response: WhatDoTheyKnow.com — Wyre Council FOI, 6 March 2026

Source for Council Leader’s call: ENDS Report, 3 March 2026.

What is not confirmed in available documents: Whether the Council Leader was consulted before the FOI response was issued; whether the FOI response reflects the council’s current policy position or a specific answer to a specific question; whether the decision was made on clinical or administrative grounds; which officer or body within Wyre Council authored the response.

What “Biomonitoring” Means Here

Human biomonitoring (HBM) for PFAS involves blood serum analysis. It establishes whether PFAS compounds are present in an individual’s body and at what concentration. It is the only method that can directly answer the question: has this person been exposed to PFAS, and at what level?

Biomonitoring does not diagnose illness. It quantifies exposure. It is recommended by international health authorities as part of PFAS exposure investigations near contaminated sites. At comparable sites — Belgium (3M Zwijndrecht), USA (DuPont Parkersburg), Netherlands (Chemours Dordrecht) — authorities established population biomonitoring programmes.

The Three Stated Reasons — and What They Imply

The FOI response offered three reasons for declining biomonitoring. Each merits examination against the public health record:

“Not appropriate”

This is a policy conclusion, not an explanation. What makes biomonitoring “not appropriate” at a site where the EA has formally concluded that land meets Contaminated Land criteria under Part 2A of the Environmental Protection Act — specifically because PFOA has been found in produce — has not been set out in documents publicly available to date.

“Uninterpretable”

The claim that blood test results would be uninterpretable raises a methodological question: uninterpretable relative to what? Without population baseline data, individual PFAS blood levels cannot easily be contextualised against a local norm. However, they can be compared against:

• General population reference values (available from UK Biobank and international studies)
• EFSA and US EPA health-based guidance values
• Values measured at other contaminated sites where biomonitoring has been conducted

At Parkersburg, Ohio, biomonitoring was conducted on 69,030 participants precisely because the data was needed to establish exposure levels before interpretation became possible. The claim of uninterpretability presupposes the absence of data that biomonitoring is specifically designed to generate.

“Additional distress”

The standard rationale for biomonitoring near contaminated sites, as described by international health authorities, is that knowing one’s exposure level enables informed decisions: about diet and consumption, about medical follow-up, and about whether remediation has reduced personal exposure over time.

The alternative — not testing — means residents have no direct data on personal exposure levels.

Whether the council’s assessment weighed the potential distress from a positive test result against the experience of residents living with unquantified exposure — and with official advice escalating from “wash and peel” (July 2024) to allotment closures and a contaminated land designation (March 2026) — is not documented in publicly available materials.

The Documented Contrast

This sequence produces a documented public record of two positions held by or expressed through Wyre Council within three days:

• 3 March 2026: The Council Leader publicly called for blood tests and a proper health inquiry
• 6 March 2026: Wyre Council’s formal FOI response declined biomonitoring on the grounds stated above

Whether these positions were coordinated, and whether the Council Leader’s public call reflects council policy or a personal position, is not established in available documents.

International Comparators

At each of the following sites, authorities established population biomonitoring programmes:

None of these sites’ authorities cited the risk of distress as a reason to withhold testing from residents living near contaminated sites.

Outstanding Questions

The following questions can be put directly to Wyre Council and relevant health bodies:

1. Which specific authority or body made the decision to decline biomonitoring?
2. Was a clinical risk assessment conducted before that decision was made?
3. Was the Council Leader informed of the FOI response before it was issued?
4. Does the FOI response reflect Wyre Council’s current policy position on biomonitoring?
5. What guidance, if any, from UKHSA informed the council’s position?
6. Has any NHS pathway for PFAS blood testing been established for local residents?

Sources for this post:

• ENDS Report, 3 March 2026 (Council Leader’s public call for blood tests)
• Wyre Council FOI response, 6 March 2026: WhatDoTheyKnow.com
• International comparators: Belgian Environment Agency (3M); C8 Science Panel Archive; Dutch Environmental Authority (Chemours)
• FSA/Wyre Council allotment closures: Wyre Council, 5 March 2026